Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373

on Behalf of the UK Primary Sjögren's Syndrome Registry

doi:10.1093/rheumatology/kex331

Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373

on Behalf of the UK Primary Sjögren's Syndrome Registry

Inflammation and Ageing

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Further to publication of this paper the Authors have identified that although all 688 participants had a clinical diagnosis of primary Sjögren's Syndrome and 668 (97.1%) fulfilled the American-European Consensus Group (AECG) classification criteria, 20 patients (2.9%) did not have sufficient features to do so. This error arose from an incorrect assumption derived from the database during analysis, for which the Authors apologize. There is no impact on the outcome or conclusions of the paper, but the methods have been amended accordingly online. The Authors also identified a small number of minor errors as follows: In the abstract the number eligible for the TEARS study is 46.3% not 31.6% (see Table 2). In Table 1: DMARD %=9.6; Pilocarpine or DMARD %=16.6; Unstimulated flow rate>1.5mls/15 mins %=15.0; Low C3%=2.0; Low C4%=17.2; Lymphoma %=4.8 (see supplementary table).

Original language	English
Pages (from-to)	2255
Number of pages	1
Journal	Rheumatology (United Kingdom)
Volume	56
Issue number	12
DOIs	https://doi.org/10.1093/rheumatology/kex331
Publication status	Published - 1 Dec 2017

Bibliographical note

Funding Information:
1Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, 2Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, 3Interdisciplinary Computing and Complex BioSystems Research Group, School of Computing Science, Newcastle University, Newcastle, 4Musculoskeletal Research Group, Institute of Cellular Medicine & Newcastle NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Newcastle University, Newcastle upon Tyne, 5Rheumatology Department, Great Western Hospitals NHS Foundation Trust, Swindon, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, 7NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, 8Rheumatology Department, Nottingham University Hospital, Nottingham, 9Department of Experimental Medicine and Rheumatology, Barts and the London NHS Trust and Barts and the London School of Medicine and Dentistry, London, 10Rheumatology Department, Gartnavel General Hospital, Glasgow, 11Rheumatology Department, NHS Fife, Whyteman’s Brae Hospital, Kirkcaldy, 12Rheumatology Department, Royal Hampshire

Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

ASJC Scopus subject areas

Rheumatology
Pharmacology (medical)

Access to Document

10.1093/rheumatology/kex331

Cite this

@article{9af25bdb6ec64f3ebe0490d8273a63fb,

title = "Corrigendum: Eligibility for clinical trials in primary Sj{\"o}gren's syndrome: Lessons from the UK Primary Sj{\"o}gren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373",

abstract = "Further to publication of this paper the Authors have identified that although all 688 participants had a clinical diagnosis of primary Sj{\"o}gren's Syndrome and 668 (97.1%) fulfilled the American-European Consensus Group (AECG) classification criteria, 20 patients (2.9%) did not have sufficient features to do so. This error arose from an incorrect assumption derived from the database during analysis, for which the Authors apologize. There is no impact on the outcome or conclusions of the paper, but the methods have been amended accordingly online. The Authors also identified a small number of minor errors as follows: In the abstract the number eligible for the TEARS study is 46.3% not 31.6% (see Table 2). In Table 1: DMARD %=9.6; Pilocarpine or DMARD %=16.6; Unstimulated flow rate>1.5mls/15 mins %=15.0; Low C3%=2.0; Low C4%=17.2; Lymphoma %=4.8 (see supplementary table).",

author = "{on Behalf of the UK Primary Sj{\"o}gren's Syndrome Registry} and Clare Oni and Sheryl Mitchell and Katherine James and Ng, {Wan Fai} and Bridget Griffiths and Victoria Hindmarsh and Elizabeth Price and Pease, {Colin T.} and Paul Emery and Peter Lanyon and Adrian Jones and Michele Bombardieri and Nurhan Sutcliffe and Costantino Pitzalis and John Hunter and Monica Gupta and John McLaren and Annie Cooper and Marian Regan and Ian Giles and David Isenberg and Vadivelu Saravanan and David Coady and Bhaskar Dasgupta and Neil McHugh and Steven Young-Min and Robert Moots and Nagui Gendi and Mohammed Akil and Francesca Barone and Ben Fisher and Saaeha Rauz and Andrea Richards and Bowman, {Simon J.}",

note = "Funding Information: 1Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, 2Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, 3Interdisciplinary Computing and Complex BioSystems Research Group, School of Computing Science, Newcastle University, Newcastle, 4Musculoskeletal Research Group, Institute of Cellular Medicine & Newcastle NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Newcastle University, Newcastle upon Tyne, 5Rheumatology Department, Great Western Hospitals NHS Foundation Trust, Swindon, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, 7NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, 8Rheumatology Department, Nottingham University Hospital, Nottingham, 9Department of Experimental Medicine and Rheumatology, Barts and the London NHS Trust and Barts and the London School of Medicine and Dentistry, London, 10Rheumatology Department, Gartnavel General Hospital, Glasgow, 11Rheumatology Department, NHS Fife, Whyteman{\textquoteright}s Brae Hospital, Kirkcaldy, 12Rheumatology Department, Royal Hampshire Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.",

year = "2017",

month = dec,

day = "1",

doi = "10.1093/rheumatology/kex331",

language = "English",

volume = "56",

pages = "2255",

journal = "Rheumatology (United Kingdom)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "12",

}

on Behalf of the UK Primary Sjögren's Syndrome Registry 2017, 'Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373', Rheumatology (United Kingdom), vol. 56, no. 12, pp. 2255. https://doi.org/10.1093/rheumatology/kex331

Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373. / on Behalf of the UK Primary Sjögren's Syndrome Registry.
In: Rheumatology (United Kingdom), Vol. 56, No. 12, 01.12.2017, p. 2255.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum

T2 - Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373

AU - on Behalf of the UK Primary Sjögren's Syndrome Registry

AU - Oni, Clare

AU - Mitchell, Sheryl

AU - James, Katherine

AU - Ng, Wan Fai

AU - Griffiths, Bridget

AU - Hindmarsh, Victoria

AU - Price, Elizabeth

AU - Pease, Colin T.

AU - Emery, Paul

AU - Lanyon, Peter

AU - Jones, Adrian

AU - Bombardieri, Michele

AU - Sutcliffe, Nurhan

AU - Pitzalis, Costantino

AU - Hunter, John

AU - Gupta, Monica

AU - McLaren, John

AU - Cooper, Annie

AU - Regan, Marian

AU - Giles, Ian

AU - Isenberg, David

AU - Saravanan, Vadivelu

AU - Coady, David

AU - Dasgupta, Bhaskar

AU - McHugh, Neil

AU - Young-Min, Steven

AU - Moots, Robert

AU - Gendi, Nagui

AU - Akil, Mohammed

AU - Barone, Francesca

AU - Fisher, Ben

AU - Rauz, Saaeha

AU - Richards, Andrea

AU - Bowman, Simon J.

N1 - Funding Information: 1Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, 2Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, 3Interdisciplinary Computing and Complex BioSystems Research Group, School of Computing Science, Newcastle University, Newcastle, 4Musculoskeletal Research Group, Institute of Cellular Medicine & Newcastle NIHR Biomedical Research Centre for Ageing and Chronic Diseases, Newcastle University, Newcastle upon Tyne, 5Rheumatology Department, Great Western Hospitals NHS Foundation Trust, Swindon, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, 7NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, 8Rheumatology Department, Nottingham University Hospital, Nottingham, 9Department of Experimental Medicine and Rheumatology, Barts and the London NHS Trust and Barts and the London School of Medicine and Dentistry, London, 10Rheumatology Department, Gartnavel General Hospital, Glasgow, 11Rheumatology Department, NHS Fife, Whyteman’s Brae Hospital, Kirkcaldy, 12Rheumatology Department, Royal Hampshire Publisher Copyright: © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Further to publication of this paper the Authors have identified that although all 688 participants had a clinical diagnosis of primary Sjögren's Syndrome and 668 (97.1%) fulfilled the American-European Consensus Group (AECG) classification criteria, 20 patients (2.9%) did not have sufficient features to do so. This error arose from an incorrect assumption derived from the database during analysis, for which the Authors apologize. There is no impact on the outcome or conclusions of the paper, but the methods have been amended accordingly online. The Authors also identified a small number of minor errors as follows: In the abstract the number eligible for the TEARS study is 46.3% not 31.6% (see Table 2). In Table 1: DMARD %=9.6; Pilocarpine or DMARD %=16.6; Unstimulated flow rate>1.5mls/15 mins %=15.0; Low C3%=2.0; Low C4%=17.2; Lymphoma %=4.8 (see supplementary table).

AB - Further to publication of this paper the Authors have identified that although all 688 participants had a clinical diagnosis of primary Sjögren's Syndrome and 668 (97.1%) fulfilled the American-European Consensus Group (AECG) classification criteria, 20 patients (2.9%) did not have sufficient features to do so. This error arose from an incorrect assumption derived from the database during analysis, for which the Authors apologize. There is no impact on the outcome or conclusions of the paper, but the methods have been amended accordingly online. The Authors also identified a small number of minor errors as follows: In the abstract the number eligible for the TEARS study is 46.3% not 31.6% (see Table 2). In Table 1: DMARD %=9.6; Pilocarpine or DMARD %=16.6; Unstimulated flow rate>1.5mls/15 mins %=15.0; Low C3%=2.0; Low C4%=17.2; Lymphoma %=4.8 (see supplementary table).

UR - http://www.scopus.com/inward/record.url?scp=85042214263&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kex331

DO - 10.1093/rheumatology/kex331

M3 - Comment/debate

C2 - 28968900

AN - SCOPUS:85042214263

SN - 1462-0324

VL - 56

SP - 2255

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

IS - 12

ER -

Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this